For investors seeking momentum, iShares S&P Small-Cap 600 Growth ETF (IJT - Free Report) is probably on the radar now. The fund just hit a 52-week high and is up nearly 35.4% from its 52-week low price of $149.00/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed.
IJT in Focus
The fund measures the performance of the small-capitalization growth sector of the U.S. equity market. Ligand Pharmaceuticals, Trex and Healthequity are the top three holdings of the fund. Industrials (21.74%), Health Care (19.02%), Information Technology (16.30%), Financials (13.39%) and Consumer Discretionary (12.53%) are the top five sectors of the fund. The product charges 25 bps in fees (see all Small Cap ETFs here).
Why the Move?
The present economic momentum is solid in the United States with the tax reform underway and several U.S. economic data coming in better than other developed economies. An improving U.S. economy, a rising greenback and geopolitical concerns pushed investors toward the more domestically-focused small-cap stocks. All these have boosted this small-cap ETF.
More Gains Ahead?
The fund has a Zacks Rank #1 (Strong Buy). Plus, it seems that the fund will perform decently in the near term given a positive weighted alpha of 33.40.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For investors seeking momentum, iShares S&P Small-Cap 600 Growth ETF (IJT - Free Report) is probably on the radar now. The fund just hit a 52-week high and is up nearly 35.4% from its 52-week low price of $149.00/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed.
IJT in Focus
The fund measures the performance of the small-capitalization growth sector of the U.S. equity market. Ligand Pharmaceuticals, Trex and Healthequity are the top three holdings of the fund. Industrials (21.74%), Health Care (19.02%), Information Technology (16.30%), Financials (13.39%) and Consumer Discretionary (12.53%) are the top five sectors of the fund. The product charges 25 bps in fees (see all Small Cap ETFs here).
Why the Move?
The present economic momentum is solid in the United States with the tax reform underway and several U.S. economic data coming in better than other developed economies. An improving U.S. economy, a rising greenback and geopolitical concerns pushed investors toward the more domestically-focused small-cap stocks. All these have boosted this small-cap ETF.
More Gains Ahead?
The fund has a Zacks Rank #1 (Strong Buy). Plus, it seems that the fund will perform decently in the near term given a positive weighted alpha of 33.40.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on IJT - FREE